Abiopharma

🔍 ORBIMED ADVISORS LLC (Executive)

Company: Enliven Therapeutics, Inc. (ELVN)

Report Date: 2026-06-22

Detailed Transactions and Holdings:

• Sold 24,846 shares of Common Stock at $45.38 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 220,882.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,477 shares of Common Stock at $45.0 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 219,405.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 787,024 shares of Common Stock at $45.38 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,601,878.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 46,776 shares of Common Stock at $45.0 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,555,102.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
• F2: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
• F3: This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.